Uni-Bio Science Group Limited
Uni-Bio Science Group Limited Fundamental Analysis
Uni-Bio Science Group Limited (0690.HK) shows moderate financial fundamentals with a PE ratio of 6.34, profit margin of 15.49%, and ROE of 25.79%. The company generates $0.6B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 73.5/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 0690.HK's fundamental strength across five key dimensions:
Efficiency Score
Excellent0690.HK demonstrates superior asset utilization.
Valuation Score
Excellent0690.HK trades at attractive valuation levels.
Growth Score
Moderate0690.HK shows steady but slowing expansion.
Financial Health Score
Excellent0690.HK maintains a strong and stable balance sheet.
Profitability Score
Excellent0690.HK achieves industry-leading margins.
Key Financial Metrics
Is 0690.HK Expensive or Cheap?
P/E Ratio
0690.HK trades at 6.34 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 0690.HK's PEG of 0.47 indicates potential undervaluation.
Price to Book
The market values Uni-Bio Science Group Limited at 1.51 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 5.25 times EBITDA. This is generally considered low.
How Well Does 0690.HK Make Money?
Net Profit Margin
For every $100 in sales, Uni-Bio Science Group Limited keeps $15.49 as profit after all expenses.
Operating Margin
Core operations generate 1.29 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $25.79 in profit for every $100 of shareholder equity.
ROA
Uni-Bio Science Group Limited generates $16.43 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Uni-Bio Science Group Limited produces operating cash flow of $70.93M, showing steady but balanced cash generation.
Free Cash Flow
Uni-Bio Science Group Limited produces free cash flow of $32.93M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.01 in free cash annually.
FCF Yield
0690.HK converts 5.69% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
6.34
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.47
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.51
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.98
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.28
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.40
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.26
vs 25 benchmark
ROA
Return on assets percentage
0.16
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How 0690.HK Stacks Against Its Sector Peers
| Metric | 0690.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 6.34 | 28.31 | Better (Cheaper) |
| ROE | 25.79% | 699.00% | Weak |
| Net Margin | 15.49% | -130884.00% (disorted) | Strong |
| Debt/Equity | 0.28 | 0.34 | Neutral |
| Current Ratio | 3.40 | 2775.16 | Strong Liquidity |
| ROA | 16.43% | -14469.00% (disorted) | Strong |
0690.HK outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Uni-Bio Science Group Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation